Regulator requires Ozempic, Wegovy, and Mounjaro to carry warning in the US regarding vision loss risk

The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, to add warnings to their labels regarding a potential risk of non-arteritic anterior ischemic optic neuropathy (NAION). This condition, which can cause sudden, painless, and potentially permanent vision loss, is being monitored following reports and clinical data, though a direct causal link is not yet established.